Cargando…

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

Detalles Bibliográficos
Autores principales:	Baden, Lindsey R., El Sahly, Hana M., Essink, Brandon, Follmann, Dean, Neuzil, Kathleen M., August, Allison, Clouting, Heather, Fortier, Gabrielle, Deng, Weiping, Han, Shu, Zhao, Xiaoping, Leav, Brett, Talarico, Carla, Girard, Bethany, Paila, Yamuna D., Tomassini, Joanne E., Schödel, Florian, Pajon, Rolando, Zhou, Honghong, Das, Rituparna, Miller, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609569/ https://www.ncbi.nlm.nih.gov/pubmed/34731553 http://dx.doi.org/10.1056/NEJMc2115597

Ejemplares similares

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022)

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
por: Pajon, Rolando, et al.
Publicado: (2022)

mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children
por: Girard, Bethany, et al.
Publicado: (2022)

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
por: El Sahly, Hana M., et al.
Publicado: (2021)

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
por: Ali, Kashif, et al.
Publicado: (2021)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020)

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
por: Chalkias, Spyros, et al.
Publicado: (2022)

1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves
por: Follmann, Dean, et al.
Publicado: (2023)

Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial
por: Lin, Dan-Yu, et al.
Publicado: (2022)

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
por: Chu, Laurence, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
por: Shen, Xiaoying, et al.
Publicado: (2022)

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
por: Chalkias, Spyros, et al.
Publicado: (2022)

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
por: Chu, Laurence, et al.
Publicado: (2021)

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
por: Creech, C. Buddy, et al.
Publicado: (2022)

367. Safety and Immunogenicity of a 50-μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in Adolescents
por: Figueroa, Amparo, et al.
Publicado: (2023)

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
por: Anderson, Evan J., et al.
Publicado: (2022)

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
por: Gilbert, Peter B., et al.
Publicado: (2021)

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
por: Gilbert, Peter B., et al.
Publicado: (2021)

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
por: Huang, Ying, et al.
Publicado: (2023)

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
por: Benkeser, David, et al.
Publicado: (2023)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2023)

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
por: Choi, Angela, et al.
Publicado: (2021)

Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial
por: Jochum, Simon, et al.
Publicado: (2021)

Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial
por: Jochum, Simon, et al.
Publicado: (2022)

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
por: Choi, Angela, et al.
Publicado: (2021)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273)
por: Leav, Brett, et al.
Publicado: (2022)

Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19
por: Kirste, Imke, et al.
Publicado: (2022)

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
por: Chalkias, Spyros, et al.
Publicado: (2023)

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS
por: Naficy, A., et al.
Publicado: (2023)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
por: Widge, Alicia T., et al.
Publicado: (2020)

Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
por: Giuliano, Anna, et al.
Publicado: (2023)

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
por: Doria-Rose, Nicole, et al.
Publicado: (2021)

A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus
por: August, Allison, et al.
Publicado: (2021)

Author Correction: A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus
por: August, Allison, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7np49sjdp3pehl7h9d8lf2g5t5